Gem/nab-P Chemotherapy

PreclinicalSmall molecule

Gem/nab-P Chemotherapy is one of 33 small molecule programs targeting Pancreatic Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Pancreatic CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Pancreatic Carcinoma

#DrugCompanyPhaseTrials

Lynparza

Gemzar

6 3

Eloxatin

Teva

Phase 3

1 4

Camptosar

Pfizer

Phase 3

1 5

Imfinzi

Folinic Acid

1 7

BMS-986205

Iressa

1 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 10

Tuoyi

SSun Yat-sen University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Pancreatic Carcinoma

NCT05869474

Clinical

Trials by Indication[1]

Pancreatic Carcinoma1 trial

Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma

Recruiting·—·N/A·NCT05869474·206 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gem/nab-P Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gem/nab-P Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gem/nab-P Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changhai Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CChanghai Hospital

Gem/nab-P Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pancreatic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News